See also this year's filing and all EDGAR filings for this company.
PDF Report 0000744218_2013_Celldex_Therapeutics_Inc.pdf
Logs
| info | NetIncome node detected by revenue/expenses heuristic | input.sec.calculation_linkbase.edgar_model_mapping | {'net_inc_node': 'OperatingIncomeLoss'} |
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'0020 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS': 12, '0021 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPRENHENSIVE LOSS (CALC 2)': 3}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0000744218, Celldex Therapeutics Inc
| xvar | xval | |
|---|---|---|
| 0 | LiabilitiesNoncurrent | 6,336,000 |
| 1 | LiabilitiesCurrent | 17,685,000 |
| 2 | remainder_Liabilities | 5,746,000 |
| 3 | AssetsCurrent | 85,114,000 |
| 4 | AssetsNoncurrent | 424,000 |
| 5 | PropertyPlantAndEquipmentNet | 7,205,000 |
| 6 | Goodwill | 32,798,000 |
| 7 | remainder_Assets | 0 |
| 8 | GeneralAndAdministrativeExpense | 10,016,000 |
| 9 | ResearchAndDevelopmentExpense | 47,398,000 |
| 10 | remainder_Expenses | 11,865,000 |
| 11 | remainder_Revenues | 11,202,000 |
| 12 | remainder_NetIncome | 0 |
| 13 | remainder_ComprehensiveNetIncome | -953,000 |
| yvar | yval | |
|---|---|---|
| 0 | Liabilities | 29,767,000 |
| 1 | Assets | 125,541,000 |
| 2 | Expenses | 69,279,000 |
| 3 | Revenues | 11,202,000 |
| 4 | StockholdersEquity | 95,774,000 |
| 5 | NetIncome | -58,077,000 |
| 6 | ComprehensiveNetIncome | -58,553,500 |
| 7 | BaseVar | 118,371,000 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 0.936 |
| 9 | EconomicCapitalRatio | 1.63 |
Edgar->Model Mapping
Feature Distribution
Change over Time
